Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

The naturally occurring oncolytic herpes simplex virus canerpaturev (C-REV), formerly HF10, proved its therapeutic efficacy and safety in multiple clinical trials against melanoma, pancreatic, breast, and head and neck cancers. Meanwhile, patients with colorectal cancer, which has increased in preva...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhiwen, Ichinose, Toru, Naoe, Yoshinori, Matsumura, Shigeru, Villalobos, Itzel Bustos, Eissa, Ibrahim Ragab, Yamada, Suguru, Miyajima, Noriyuki, Morimoto, Daishi, Mukoyama, Nobuaki, Nishikawa, Yoko, Koide, Yusuke, Kodera, Yasuhiro, Tanaka, Maki, Kasuya, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539424/
https://www.ncbi.nlm.nih.gov/pubmed/31193737
http://dx.doi.org/10.1016/j.omto.2019.04.004

Ejemplares similares

Ejemplares similares